NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Supply)
- Duration
- 2 year (est.)
- Value
- £1
- Sector
- HEALTH
- Published
- 04 Jul 2022
- Delivery
- 01 Jul 2022 to 30 Jun 2024 (est.)
- Deadline
- n/a
Concepts
Location
ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above
Geochart for 2 buyers and 25 suppliers
2 buyers
- NHS England Leeds
8 suppliers
- Octapharma Manchester
- CSL Behring Haywards Heath
- Takeda London
- LFB Letchworth Garden City
- Novo Nordisk Gatwick
- Bio Products Laboratory Elstree
- Pfizer Tadworth
- Sobi Swedish Orphan Biovitrum Great Abington
Description
National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 moths. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Lot Division
| 1 | eftrenonacog alfa (rFIX EHL) eftrenonacog alfa (rFIX EHL) Award Criteria
| ||||||
| 2 | albutrepenonacog alfa (rFIX EHL) albutrepenonacog alfa (rFIX EHL) Award Criteria
| ||||||
| 3 | nonacog beta pegol (rFIX EHL) nonacog beta pegol (rFIX EHL) Award Criteria
| ||||||
| 4 | rFIX - Standard Half Life rFIX - Standard Half Life Award Criteria
| ||||||
| 5 | Recombinant Factor VII Recombinant Factor VII Award Criteria
| ||||||
| 6 | Porcine Factor VIII - susoctocog alfa Porcine Factor VIII - susoctocog alfa Award Criteria
| ||||||
| 7 | Factor VIII Inhibitor Bypassing Fraction Factor VIII Inhibitor Bypassing Fraction Award Criteria
| ||||||
| 8 | Factor IX - High Purity Factor IX Factor IX - High Purity Factor IX Award Criteria
| ||||||
| 9 | Factor X Factor X Award Criteria
| ||||||
| 10 | Factor XIII - Plasma Derived Factor XIII - Plasma Derived Award Criteria
| ||||||
| 11 | Factor XIII - Recombinant Factor XIII - Recombinant Award Criteria
| ||||||
| 12 | Factor VIII/ von willebrands factor Factor VIII/ von willebrands factor Award Criteria
| ||||||
| 13 | Von willebrands factor - Plasma Derived Von willebrands factor - Plasma Derived Award Criteria
| ||||||
| 14 | Von willebrands factor - Recombinant Von willebrands factor - Recombinant Award Criteria
| ||||||
| 15 | Fibrinogen Concentrate Fibrinogen Concentrate Award Criteria
| ||||||
| 16 | Prothrombin Complex dried Prothrombin Complex dried Award Criteria
| ||||||
| 17 | Protein C Concentrate Protein C Concentrate Award Criteria
| ||||||
| 18 | Fresh Frozen Plasma Fresh Frozen Plasma Award Criteria
|
Award Detail
| 1 | Octapharma (Manchester)
|
| 2 | Octapharma (Manchester)
|
| 3 | CSL Behring (Haywards Heath)
|
| 4 | Takeda (London)
|
| 5 | Octapharma (Manchester)
|
| 6 | CSL Behring (Haywards Heath)
|
| 7 | LFB (Letchworth Garden City)
|
| 8 | Takeda (London)
|
| 9 | Takeda (London)
|
| 10 | CSL Behring (Haywards Heath)
|
| 11 | Novo Nordisk (Gatwick)
|
| 12 | Bio Products Laboratory (Elstree)
|
| 13 | Bio Products Laboratory (Elstree)
|
| 14 | Takeda (London)
|
| 15 | LFB (Letchworth Garden City)
|
| 16 | Octapharma (Manchester)
|
| 17 | CSL Behring (Haywards Heath)
|
| 18 | Takeda (London)
|
| 19 | Novo Nordisk (Gatwick)
|
| 20 | LFB (Letchworth Garden City)
|
| 21 | Pfizer (Tadworth)
|
| 22 | Takeda (London)
|
| 23 | Novo Nordisk (Gatwick)
|
| 24 | CSL Behring (Haywards Heath)
|
| 25 | Sobi Swedish Orphan Biovitrum (Great Abington)
|
CPV Codes
- 33141530 - Blood coagulants
Indicators
- Options are available.
- Award on basis of price.
Reference
- FTS 018165-2022